2. Search Result
Search Result
Results for "

Haemophilus

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10004
    Faropenem daloxate

    Faropenem medoxil

    		 Antibiotic Bacterial Infection
    Faropenem daloxate (Faropenem medoxil) is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis .
    Faropenem daloxate
  • HY-14956
    Nemonoxacin

    TG-873870

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin
  • HY-19892A
    Brilacidin tetrahydrochloride
    1 Publications Verification

    PMX 30063 tetrahydrochloride

    		 Bacterial Antibiotic Infection Cancer
    Brilacidin tetrahydrochloride (PMX 30063 tetrahydrochloride) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin tetrahydrochloride is a defensin mimetic antibiotic compound .
    Brilacidin tetrahydrochloride
  • HY-126463
    LolCDE-IN-4

    		Bacterial Infection
    LolCDE-IN-4 (Compound 1) is exhibits antibacterial efficacy against gram negative bacteria Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae, through inhibition LolCDE complex and disruption of lipoproteins release from the inner membrane .
    LolCDE-IN-4
  • HY-W023253
    Biclotymol

    		Bacterial Fungal Infection Inflammation/Immunology
    Biclotymol is an antimicrobial agent against gram-positive cocci. Biclotymol inhibits Streptococcus pneumoniae and Haemophilus influenzae, with MIC of 150 and 150 μM. Biclotymol exhibits anti-inflammatory and analgesic activity and ameliorates the otolaryngology infection and throat sore .
    Biclotymol
  • HY-161788
    DNA Gyrase-IN-11

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-11 (Compound 23Be) is an inhibitor for protein synthesis (IC50 is 0.74 μM) and DNA replication. DNA Gyrase-IN-11 inhibits DNA gyrase, that inhibits E. coli DNA supercoiling with IC50 of 11.9 μM. DNA Gyrase-IN-11 exhibits antibacterial efficacy, that inhibits Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Staphylococcus aureus, with MICs of 0.008-0.25 μg/mL .
    DNA Gyrase-IN-11
  • HY-129914
    Cefcanel daloxate

    KY-109 free base

    		 Bacterial Infection
    Cefcanel daloxate (KY-109 (free base)) is an orally active cephalosporin prodrug against Gram-positive bacteria and Haemophilus influenzae. Cefcanel daloxate is promising for research of uremia .
    Cefcanel daloxate
  • HY-W747311
    Ritipenem

    		Antibiotic Bacterial Penicillin-binding protein (PBP) Infection
    Ritipenem is a penicillin antibiotic, that targets penicillin-binding protein with good affinity (IC50 in levels of ng/mL), and exhibits antibacterial properties. Ritipenem exhibits antiviral activity against Haemophilus influenzae .
    Ritipenem
  • HY-N14906
    4-Diazo-3-methoxy-2,5-cyclohexadien-1-one

    		Bacterial Infection
    4-Diazo-3-methoxy-2,5-cyclohexadien-1-one has favourable anti-anaerobe activity. MIC: 0.4 μg/mL for Clostridium and Bacterioids, 0.2 μg/mL for Haemophilus .
    4-Diazo-3-methoxy-2,5-cyclohexadien-1-one
  • HY-19892
    Brilacidin

    PMX 30063

    		 Bacterial Antibiotic Infection Cancer
    Brilacidin (PMX 30063) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin is a defensin mimetic antibiotic compound .
    Brilacidin
  • HY-157363
    Tryptone Soya Agar

    		Biochemical Assay Reagents Others
    Tryptone Soya Agar is a general-purpose culture medium for the isolation and cultivation of fastidious and non-fastidious microorganisms or the maintenance of stock culture.
    Tryptone Soya Agar
  • HY-121329
    Carumonam

    AMA-1080; Ro 17-2301

    		 Penicillin-binding protein (PBP) Antibiotic Bacterial Infection
    Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP). Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis .
    Carumonam
  • HY-B0958
    Mupirocin

    BRL-4910A; Pseudomonic acid

    		 Bacterial Antibiotic Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin
  • HY-17593
    Solithromycin
    3 Publications Verification

    CEM-101; OP-1068

    		 Bacterial Antibiotic Infection
    Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC50s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .
    Solithromycin
  • HY-159687
    Nafithromycin

    WCK 4873

    		 Antibiotic Bacterial Infection
    Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .
    Nafithromycin
  • HY-14956S
    Nemonoxacin-d3

    TG-873870-d3

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d3 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin-d3
  • HY-14956S1
    Nemonoxacin-d3-1

    TG-873870-d3-1

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d3-1 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin-d3-1
  • HY-14956S2
    Nemonoxacin-d4

    TG-873870-d4

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d4 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin-d4
  • HY-W108875
    Mupirocin lithium

    BRL-4910A lithium; Pseudomonic acid lithium

    		 Antibiotic Bacterial Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin lithium
  • HY-172390
    Florfenicol-propanoate-piperidin

    		Bacterial Infection
    Florfenicol-propanoate-piperidin (Compound 1) is the derivative of Florfenicol (HY-B1374). Florfenicol-propanoate-piperidin exhibits antibacterial activity, inhibits E. coli ATCC25922, Salmonella CICC110420, S. aureus ATCC29213, B. subtilis CMCC(B)63501, E. faecalis ATCC29212, S. suis CVCC606, and Haemophilus parasuis with MIC of 2-8 μM .
    Florfenicol-propanoate-piperidin
  • HY-17593R
    Solithromycin (Standard)

    CEM-101 (Standard); OP-1068 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Solithromycin (Standard) is the analytical standard of Solithromycin. This product is intended for research and analytical applications. Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC50s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .
    Solithromycin (Standard)
  • HY-135221
    Cefcapene pivoxil hydrochloride

    		Bacterial Antibiotic Infection
    Cefcapene pivoxil hydrochloride, the pivalate ester prodrug form of Cefcapene, is an orally active third-generation cephalosporin with a wide spectrum of anti-bacterial activity. Cefcapene pivoxil hydrochloride has the potential for the palmoplantar pustulosis (PPP) research .
    Cefcapene pivoxil hydrochloride
  • HY-135221R
    Cefcapene pivoxil hydrochloride (Standard)

    		Reference Standards Bacterial Antibiotic Infection
    Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Cefcapene pivoxil hydrochloride (Standard)
  • HY-B0435
    Roxithromycin
    5 Publications Verification

    RU-28965

    		 Bacterial Antibiotic Apoptosis p38 MAPK NF-κB Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Roxithromycin (RU-28965) is an orally active semi-synthethic macrolide antibiotic. Roxithromycin inhibits protein biosynthesis in the elongation step by binding to 50S bacterial ribosome. Roxithromycin has antimicrobial, antiproliferative, anti-inflammatory, tumour vasculature inhibiting and lung injury ameliorating effects .
    Roxithromycin
  • HY-B0958R
    Mupirocin (Standard)

    BRL-4910A (Standard); Pseudomonic acid (Standard)

    		 Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin (Standard)
  • HY-10004R
    Faropenem daloxate (Standard)

    Faropenem medoxil (Standard)

    		 Reference Standards Antibiotic Bacterial Infection
    Faropenem daloxate (Faropenem medoxil) (Standard) is the analytical standard of Faropenem daloxate (Faropenem medoxil). This product is intended for research and analytical applications. Faropenem daloxate is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis .
    Faropenem daloxate (Standard)
  • HY-W108875R
    Mupirocin lithium (Standard)

    BRL-4910A lithium (Standard); Pseudomonic acid lithium (Standard)

    		 Antibiotic Bacterial Reference Standards Aminoacyl-tRNA Synthetase Infection Endocrinology
    Mupirocin (lithium) (Standard) is the analytical standard of Mupirocin lithium (HY-W108875). This product is intended for research and analytical applications. Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .
    Mupirocin lithium (Standard)
  • HY-125579
    Ro 25-0534

    		Bacterial Infection
    Ro 25-0534 is an antimicrobial compound against Pseudomonas. Ro 25-0534 is active against Enterobacteriaceae (MIC90: 0.06-2 μg/mL), Oxacillin (HY-B0465)-susceptible staphylococci, β-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC90: 1-2 μg/mL), Haemophilus influenzae (MIC90: 0.25-0.5 μg/mL), Moraxella catarrhalis (MIC90: 0.5 μg/mL), and most nonenteric Gram-negative bacilli (MIC90: 2-4 μg/mL) .
    Ro 25-0534
  • HY-19428
    Ranbezolid

    RBx7644 free base

    		 Antibiotic Bacterial Infection
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with a IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid
  • HY-N7101
    Cefpodoxime Proxetil

    U-76,252; CS-807

    		 Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime Proxetil
  • HY-N7101R
    Cefpodoxime Proxetil (Standard)

    U-76,252 (Standard); CS-807 (Standard)

    		 Reference Standards Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime Proxetil (Standard) is the analytical standard of Cefpodoxime Proxetil. This product is intended for research and analytical applications. Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime Proxetil (Standard)
  • HY-116815
    Lalistat 1

    		Beta-lactamase Bacterial Infection Neurological Disease
    Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .
    Lalistat 1
  • HY-121195
    Apalcillin

    PC-904

    		 Bacterial Infection
    Apalcillin (PC-904) in combination with Ro 48-1220, a penam sulfone β-lactamase inhibitor, demonstrated broad-spectrum activity against gram-negative aerobic and anaerobic bacteria, excluding Klebsiella oxytoca. It exhibited potent activity against β-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae, and Neisseria gonorrhoeae, with effective MICs (11 μg/mL). The combination also inhibited Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species at low MICs (0.25 to 4 μg/mL). However, its efficacy against oxacillin-resistant staphylococci and certain gram-positive organisms was limited. Apalcillin/Ro 48-1220 showed comparable efficacy to piperacillin/tazobactam against some extended-spectrum β-lactamase-producing Escherichia coli but was less effective against SHV-type β-lactamases .
    Apalcillin
  • HY-B0396
    Tebipenem pivoxil

    L084

    		 Penicillin-binding protein (PBP) Bacterial Antibiotic Infection
    Tebipenem pivoxil (L084) is an orally active antibiotic against a variety of pathogenic bacteria. Tebipenem pivoxil binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis .
    Tebipenem pivoxil
  • HY-B0396R
    Tebipenem pivoxil (Standard)

    L084 (Standard)

    		 Penicillin-binding protein (PBP) Reference Standards Bacterial Antibiotic Infection
    Tebipenem pivoxil (Standard) is the analytical standard of Tebipenem pivoxil. This product is intended for research and analytical applications. Tebipenem pivoxil (L084) is an orally active antibiotic against a variety of pathogenic bacteria. Tebipenem pivoxil binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis[1].
    Tebipenem pivoxil (Standard)
  • HY-B0396A
    Tebipenem pivoxil hydrochloride

    L084 hydrochloride

    		 Penicillin-binding protein (PBP) Bacterial Antibiotic Infection
    Tebipenem pivoxil (L084) hydrochloride is an orally active antibiotic against a variety of pathogenic bacteria. Tebipenem pivoxil hydrochloride binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis .
    Tebipenem pivoxil hydrochloride
  • HY-B1325
    Cefuroxime axetil

    		Bacterial Antibiotic Infection Inflammation/Immunology
    Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime (HY-B1256A) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance .
    Cefuroxime axetil
  • HY-N7101S
    Cefpodoxime proxetil-d7

    U-76-d7,252-d7; CS-807-d7

    		 Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime proxetil-d7 (U-76-d7,252-d7; CS-807-d7) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime proxetil-d7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: